한글목차

개요

세계 국소 분절 사구체 경화증(FSGS) 치료제 시장은 2023년 7억 달러에 달했습니다. 2031년에는 14억 달러에 달할 것으로 예상되며, 2024-2031년의 예측 기간 동안 연평균 7.5%의 성장률을 나타낼 전망입니다..

초발성 국소 분절 사구체 경화증(FSGS)은 사구체라는 신장의 작은 여과 단위에 영향을 미치는 신장 질환의 일종으로, 신장 흉터화를 동반합니다. 자가면역질환, 유전적 요인, 다른 신체 부위 감염, 경화성 질환 등 여러 요인에 의해 발생합니다.

사구체 손상 및 공격으로 신장 기능에 영향을 미치는 희귀질환 중 하나입니다. 신장 결함은 보통 비만, 겸상 적혈구 빈혈, 폐쇄성 수면무호흡증, 출산, HIV 등 바이러스에 의해 발생합니다.

시장 역학

성장 촉진요인

국소 분절 사구체 경화증(FSGS) 치료제(FSGS) 부담 증가

전 세계 국소 분절 사구체 경화증(FSGS) 치료제 시장 수요는 여러 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 FSGS의 부담 증가입니다. FSGS는 혈액에서 노폐물을 걸러내는 신장의 작은 부분인 사구체에 흉터 조직이 생기는 질환입니다.

FSGS는 다양한 질병에 의해 발생하며, FSGS는 신부전으로 이어질 수 있는 심각한 질병으로 투석이나 신장 이식으로만 치료할 수 있습니다.

2023년 8월 NCBI 연구 발표에 따르면, 국소 국소 분절 사구체 경화증(FSGS)(FSGS)은 신증후군의 원인으로 자주 발생하는 질환으로 성인의 40%, 소아의 20%를 차지합니다.

또한, 새로운 치료법 개발에 대한 높은 관심도 예측 기간 동안 이 시장의 성장을 가속할 것으로 예상됩니다. 예를 들어, 2023년 2월, 스퍼센틴(Sparsentan)이라는 약물이 급속한 질병 진행 위험이 있는 원발성 면역글로불린 A 신증(IgAN) 환자의 치료제로 FDA의 조기 승인을 획득했습니다.

IgAN뿐만 아니라, Travele은 또한 신장의 노폐물 필터인 사구체에 흉터 조직이 생기는 희귀한 신장 질환인 FSGS를 치료하는 약물도 개발 중입니다. 복용하고 있습니다.

제약조건

높은 투석 및 신장 이식 비용, FSGS에 대한 낮은 인지도, 제한된 치료 옵션, 엄격한 규제 및 상환 정책 등이 시장의 걸림돌로 작용할 것으로 예상됩니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter의 Five Forces 분석
• 공급망 분석
• 가격 분석
• 규제 분석
• 미충족 요구
• PESTEL 분석
• 특허 분석
• SWOT 분석

제6장 질환 유형별

• 1차성 소장 국소 분절 사구체 경화증(FSGS) 치료제
• 2차성 소장 국소 분절 사구체 경화증(FSGS) 치료제

제7장 약제별

• 부신피질 스테로이드제
• 면역 억제제
• ACE 억제제
• 안지오텐신 수용체 차단제
• 이뇨제
• 기타

제8장 투여 경로별

• 경구
• 비경구

제9장 유통 채널별

• 병원 약국
• 온라인 약국
• 소매 약국

제10장 최종사용자별

• 병원
• 전문 클리닉
• 기타

제11장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제12장 경쟁 구도

• 경쟁 시나리오
• 시장 현황/점유율 분석
• 인수합병(M&A) 분석

제13장 기업 개요

• GlaxoSmithKline plc
  • 기업 개요
  • 제품 포트폴리오와 설명
  • 재무 개요
  • 주요 발전
• Pfizer Inc
• Travere Therapeutics, Inc
• Variant Pharmaceuticals, Inc
• Dimerix
• Complexa Inc
• ChemoCentryx Inc
• AstraZeneca
• Novartis AG
• Vertex Pharmaceuticals Incorporated

제14장 부록

영문목차

Overview

The global focal segmental glomerulosclerosis drugs market reached US$ 0.7 billion in 2023 and is expected to reach US$ 1.4 billion by 2031, growing at a CAGR of 7.5% during the forecast period 2024-2031.

Focal segmental glomerulosclerosis is a type of renal disorder affecting the small filtering unit of kidneys called glomeruli which involves scarring of the kidney. It is caused by numerous factors such as autoimmune disorders, genetic factors, infection in other parts of the body, and sclerotic diseases.

It is one of the rare diseases that affects kidney function by damaging and attacking the glomeruli. Kidney defects typically characterize this disease by obesity, sickle cell anemia, obstructive sleep apnea, birth, and viruses such as HIV.

Market Dynamics

Drivers

The rising burden of focal segmental glomerulosclerosis drugs(FSGS)

The demand for the global focal segmental glomerulosclerosis drugs market is driven by multiple factors. One of the key factors is the increasing burden of FSGS. Focal segmental glomerulosclerosis drugs(FSGS) is a disease in which scar tissue develops on the glomeruli, the small parts of the kidneys that filter waste from the blood.

FSGS can be caused by a variety of conditions. FSGS is a serious condition that can lead to kidney failure, which can only be treated with dialysis or a kidney transplant.

According to an NCBI research publication in August 2023, focal segmental glomerular sclerosis (FSGS) is a frequently encountered cause of nephrotic syndrome, accounting for 40% of cases in adults and 20% in children.

In addition, a high focus on developing new treatment options is expected to drive the growth of this market over the forecast period. For instance, in February 2023, the drug, called sparsentan, snagged an FDA accelerated approval to treat patients with primary immunoglobulin A nephropathy (IgAN) who are at risk of rapid disease progression.

Moreover, IgAN, Travere is also developing Filspari for focal segmental glomerulosclerosis drugs(FSGS), an even rarer kidney disease in which scar tissue develops on the kidney's waste filter glomeruli. About 90% of patients diagnosed with IgAN are currently on an ACE inhibitor or an ARB.

Restraints

Factors such as the high cost of dialysis & kidney transplant, limited awareness of FSGS, limited availability of effective treatment options, and stringent regulatory and reimbursement policies, are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global focal segmental glomerulosclerosis drugs market is segmented based on disease type, drugs, route of administration, distribution channel, end-user, and region.

The primary focal segmental glomerulosclerosis drugs segment accounted for approximately 45.3% of the global focal segmental glomerulosclerosis drugs market share

The primary focal segmental glomerulosclerosis drugs segment is expected to hold the largest market share over the forecast period. The primary FSGS is usually "idiopathic," referring to the rise of disease without any known, definite, or apparent reason. It has several prototypical characteristics and is the most common form in adolescents and young adults.

Primary FSGS has been associated with the presence of circulating permeability factors/cytokines, which cause foot process effacement and proteinuria. These include corticotrophin-like cytokine factor 1, apoA1b, anti-CD40 Ab, and suPAR. Primary FSGS may respond to corticosteroids, immunomodulatory agents, plasmapheresis, or immunoadsorption3 and is prone to recur post-transplantation.

Moreover, key players' focus on innovative developments would propel this market growth. For instance, in May 2023, CSL Vifor announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), in focal segmental glomerulosclerosis drugs(FSGS) from its partner Travere Therapeutics.

Also, in December 2023, Travere completed a successful pre-NDA meeting for FILSPARI in IgAN. It provides regulatory updates for both IgAN and FSGS.

IgAN is the most common type of primary glomerulonephritis worldwide and a leading cause of kidney failure due to glomerular disease. IgAN is estimated to affect up to 150,000 people in the U.S. and is one of the most common glomerular diseases in Europe and Japan.

Geographical Analysis

North America accounted for approximately 42.1% of the global focal segmental glomerulosclerosis drugs market share

North America region is expected to hold the largest market share over the forecast period. The high prevalence of FSGS in North America is driving the demand for effective FSGS therapeutics. The region has a well-established research and development infrastructure that is constantly driving innovation in FSGS therapeutics. As per Springer's research publication in September 2023, FSGS is predominant in North America, accounting for 19.1% of primary glomerular diseases.

In addition, a major key player's presence, increasing awareness of FSGS among healthcare professionals, and new drug approvals would drive this market growth. For instance, in May 2022, Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan to treat IgA nephropathy (IgAN) and has granted Priority Review.

Travere Therapeutics is looking forward to working with the FDA throughout the review process to potentially deliver sparsentan to the IgA nephropathy community.

Market Segmentation

By Disease Type

• Primary Focal Segmental Glomerulosclerosis
• Secondary Focal Segmental Glomerulosclerosis

By Drugs

• Corticosteroids
• Immunosuppressive Drugs
• ACE inhibitors
• Angiotensin Receptor Blockers
• Diuretics
• Others

By Route of Administration

• Oral
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

By End-Users

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the focal segmental glomerulosclerosis drugs market include GlaxoSmithKline plc, Pfizer Inc., Travere Therapeutics, Inc., Variant Pharmaceuticals, Inc., Dimerix, Complexa Inc., ChemoCentryx Inc., AstraZeneca, Novartis AG, and Vertex Pharmaceuticals Incorporated among others.

Key Developments

• In June 2023, Delta4 identified a potential new therapeutic option for focal segmental glomerulosclerosis drugs (FSGS) using the computational hyper-C drug discovery platform. The anti-platelet drug clopidogrel was among the top predictions and was shown to alleviate disease progression in an accepted FSGS animal model, suggesting it is a promising candidate for clinical trials.
• In May 2023, Travere had to deal with the FDA after Filspari door number two opens weak in the FSGS Duplex trial.
• In February 2022 Goldfinch Bio announced positive preliminary data from a phase 2 clinical trial evaluating gfb-887 as a precision medicine for patients with focal segmental glomerulosclerosis drugs (FSGS).
• In December 2021, Vertex Pharmaceuticals Incorporated announced that in a Phase 2 proof-of-concept (POC) study in patients with APOL1-mediated focal segmental glomerulosclerosis drugs(FSGS), VX-147 on top of standard of care achieved a statistically significant, substantial and clinically meaningful mean reduction of 47.6% in the urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline.

Why Purchase the Report?

• To visualize the global focal segmental glomerulosclerosis drug market segmentation based on disease type, drugs, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global focal segmental glomerulosclerosis drugs market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global focal segmental glomerulosclerosis market report would provide approximately 78 tables, 73 figures, and 181 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Drugs
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Distribution Channel
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Rising Burden of Focal Segmental Glomerulosclerosis Drugs (FSGS)
    • 4.1.1.2. Advancements in Diagnostic Techniques
  • 4.1.2. Restraints
    • 4.1.2.1. High Cost of Dialysis & Kidney Transplant
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Primary Focal segmental glomerulosclerosis drugs*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Secondary Focal segmental glomerulosclerosis drugs

7. By Drugs

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 7.1.2. Market Attractiveness Index, By Drugs
• 7.2. Corticosteroids *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Immunosuppressive Drugs
• 7.4. ACE inhibitors
• 7.5. Angiotensin Receptor Blockers
• 7.6. Diuretics
• 7.7. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Oral*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Parenteral

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Online Pharmacies
• 9.4. Retail Pharmacies

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. UK
    • 11.3.8.3. France
    • 11.3.8.4. Italy
    • 11.3.8.5. Spain
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drugs
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. GlaxoSmithKline plc *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio & Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Pfizer Inc
• 13.3. Travere Therapeutics, Inc
• 13.4. Variant Pharmaceuticals, Inc
• 13.5. Dimerix
• 13.6. Complexa Inc
• 13.7. ChemoCentryx Inc
• 13.8. AstraZeneca
• 13.9. Novartis AG
• 13.10. Vertex Pharmaceuticals Incorporated

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us